<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03221270</url>
  </required_header>
  <id_info>
    <org_study_id>17-1364</org_study_id>
    <secondary_id>4R33MH105574-03</secondary_id>
    <nct_id>NCT03221270</nct_id>
  </id_info>
  <brief_title>Targeting Auditory Hallucinations With Alternating Current Stimulation</brief_title>
  <acronym>STILL3</acronym>
  <official_title>Targeting Auditory Hallucinations With Alternating Current Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the effects of non-invasive transcranial alternating current stimulation (tACS)
      as a treatment for auditory hallucinations in patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator's primary objective is to provide further evidence for the effectiveness of
      transcranial alternating current stimulation (tACS) to treat auditory hallucinations and to
      collect preliminary data on whether maintenance stimulation sessions can prolong the duration
      of stimulation-induced clinical benefits. The investigators will be looking into effects of
      tACS to re-normalize pathological alpha oscillations in the dorso-lateral prefrontal cortex
      (dl-PFC) of patients with schizophrenia or schizo-affective disorder by comparing Auditory
      Hallucination Rating Scale (AHRS) scores immediately before the first stimulation session,
      immediately after the last stimulation session, and at the end of the 8 weeks of maintenance
      sessions. As a secondary objective, the investigators will assess the differential clinical
      effects of active sham and 10Hz tACS on electroencephalogram (EEG) measures of alpha
      oscillations. The investigators will also be using source localization techniques in EEG
      analysis, based on individual locations of the scalp electrodes and anatomical structures
      with the use of structural magnetic resonance imaging (sMRI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will initially be randomized to either sham or 10 Hz tACS for the 5 consecutive days of stimulation. Participants will then be re-randomized to either sham or 10 Hz tACS for the 8 weeks of maintenance stimulation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double blind, randomized clinical trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Auditory Hallucination Rating Scale (AHRS)</measure>
    <time_frame>5 days from baseline measurement</time_frame>
    <description>The investigators will compare the AHRS scores from immediately before the first stimulation (baseline) and immediately after the last stimulation as the primary outcomes measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electroencephalogram (EEG)</measure>
    <time_frame>Change across time from baseline measurement to final maintenance stimulation</time_frame>
    <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first and last day of stimulation. The investigators will also collect EEG recordings data at the 1st, 3rd, and final maintenance stimulation visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>5 days from baseline measurement</time_frame>
    <description>The investigators will compare the PANSS scores from immediately before the first stimulation (baseline) and immediately after the last stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Assessment Cognition in Schizophrenia (BACS)</measure>
    <time_frame>5 days from baseline measurement</time_frame>
    <description>The investigators will compare the BACS scores immediately before the first stimulation (baseline) and immediately after the last stimulation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Electroencephalogram (EEG) Auditory Task</measure>
    <time_frame>Change across time from baseline measurement to final maintenance stimulation</time_frame>
    <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first and last day of stimulation. The investigators will also collect EEG recordings data at the 1st, 3rd, and final maintenance stimulation visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Auditory Hallucination Rating Scale (AHRS)</measure>
    <time_frame>Change from Baseline AHRS at final maintenance stimulation session.</time_frame>
    <description>The investigators will compare the AHRS scores from baseline across the 8 weeks of maintenance stimulation sessions as an outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Change from Baseline PANSS at final maintenance stimulation session.</time_frame>
    <description>The investigators will compare the PANSS scores from baseline across the 8 weeks of maintenance stimulation sessions as an outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Brief Assessment Cognition in Schizophrenia (BACS)</measure>
    <time_frame>Change from Baseline BACS at final maintenance stimulation session.</time_frame>
    <description>The investigators will compare the BACS scores from baseline across the 8 weeks of maintenance stimulation sessions as an outcome measure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizo Affective Disorder</condition>
  <arm_group>
    <arm_group_label>tACS (alpha)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 participants: 10 Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily during 5 consecutive days of stimulation, then 40 minutes once weekly for 8 weeks of maintenance stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tACS (alpha)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>20 participants: Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation, then once weekly for 8 weeks of maintenance stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tACS (alpha)</intervention_name>
    <description>Neuroconn DC Stimulator</description>
    <arm_group_label>tACS (alpha)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tACS (alpha)</intervention_name>
    <description>Neuroconn DC Stimulator</description>
    <arm_group_label>Sham tACS (alpha)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia, any subtype, or schizoaffective disorder with
             refractory hallucinations. Duration of illness &gt;1 year

          -  18 - 70 years old

          -  Clinical stable for at least 12 weeks i.e. not requiring any hospitalization or a
             change in level of care

          -  On current antipsychotic doses for at least 4 weeks

          -  Experience at least 3 auditory hallucinations per week

          -  Stable auditory hallucinations as demonstrated by having less than or equal to 20%
             change in AHRS scores across a 2 week interval during the screening period

          -  Capacity to understand all relevant risks and potential benefits of the study and to
             provide written informed consent, OR has a legal guardian who can provide the informed
             consent on the patient's behalf with the patient providing written assent to
             participate

        Exclusion Criteria:

          -  DSM-IV diagnosis of alcohol or substance abuse (other than nicotine) within the last
             month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine)
             within the last 6 months

          -  Positive urine test of cannabis, cocaine, amphetamine, barbiturates, opiates

          -  Current treatment (within 4 weeks) with psychotropic agents including benzodiazepines
             that are taken on a daily basis (limit prn use to greater than 48 hours before
             participating in a study session) or any of the following medications: carbamazepine,
             gabapentin, lamotrigine, and valproic acid

          -  Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or
             renal impairment) or treatment for a medical disorder that could interfere with study
             participation

          -  history of traumatic brain injury that required subsequent cognitive rehabilitation,
             or caused cognitive sequelae

          -  A difference of greater than 20% in AHRS scores between screening visits

          -  Prior brain surgery

          -  Any brain devices/implants, including cochlear implants and aneurysm clips

          -  Co-morbid neurological condition (e.g. seizure disorder, brain tumor)

          -  Non English speakers

          -  Female participants who are pregnant, nursing, or unwilling to use appropriate birth
             control measures during study participation

          -  Anything that, in the opinion of the investigator, would place the participant at
             increased risk or preclude the participants' full compliance with or completion of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Frohlich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina at Chapel Hill - Department of Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Criscitiello, BA</last_name>
    <phone>919-966-9929</phone>
    <email>anthony_criscitiello@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Morgan Alexander, BS,BA</last_name>
    <phone>919-966-4755</phone>
    <email>morgan_alexander@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Criscitiello, BA</last_name>
      <phone>919-966-9929</phone>
      <email>anthony_criscitiello@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Alexander, BS,BA</last_name>
      <phone>919-966-4755</phone>
      <email>morgan_alexander@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Flavio Frohlich, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091. Erratum in: Am J Psychiatry. 2012 Dec 1;169(12):1321.</citation>
    <PMID>22581236</PMID>
  </reference>
  <reference>
    <citation>Fr√∂hlich F, Burrello TN, Mellin JM, Cordle AL, Lustenberger CM, Gilmore JH, Jarskog LF. Exploratory study of once-daily transcranial direct current stimulation (tDCS) as a treatment for auditory hallucinations in schizophrenia. Eur Psychiatry. 2016 Mar;33:54-60. doi: 10.1016/j.eurpsy.2015.11.005. Epub 2016 Feb 8.</citation>
    <PMID>26866874</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tACS</keyword>
  <keyword>Sham</keyword>
  <keyword>Auditory Hallucinations</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizo Affective Disorder</keyword>
  <keyword>EEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Hallucinations</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

